Science Today

B. Pharm, S.P.E.R, Jamia Hamdard, New Delhi Race With Dreams! © 2015-2016

This man did a lot for his community. Though I not know him personally, but I often used to listen his video lectures on YouTube and sometimes his knowledge and choice of words mesmerized me. Many a times I see him as "Faizan-e-Islam" as his contribution to his community is hilarious and enormous. From a Microbiologist to VC of Jamia Hamdard, his life gives an overview to the new generation that how to be successful with limited resources. You might be wondered that he is from Gaya, Bihar and Completed his Graduation from Bihar. After that he came to Delhi where he completed his M. Phil and Ph.D from JNU, New Delhi. I also remembered his 1st job was as a Lecturer at Dept. of Botany, Delhi University to whom he said goodbye when he was abroad for post doc. This man is an inspiration to me as many a times people used to say "Always be in your stream of education, never switch over it" but my perspectives are different education is not just a tool to earn liveliho...

B. Pharm, S.P.E.R, Jamia Hamdard, New Delhi Race With Dreams! © 2015-2016 Reversible inhibition of sperm under guidance  ( RISUG ), formerly referred to as the synthetic  polymer   styrene maleic anhydride ( SMA ), is the development name of a  male contraceptive  injection developed at  IIT Kharagpur  in  India  by the team of Dr.  Sujoy K. Guha . Phase III clinical trials are underway in India, slowed by insufficient volunteers.   It has been patented in India, China, Bangladesh, and the United States.  A method based on RISUG,  Vasalgel , is currently under development in the US however there has been little or no progress in terms of bringing the product to market. Mechanism of action RISUG works by an injection into the vas deferens, the vessel through which the  sperm  moves before  ejaculation . RISUG is similar to  vasectomy  in that a local anesthetic is administered, an incision ...

A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by researchers at UCL and Imperial College London.  The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such case, known as the ‘Berlin Patient.’ Both patients were treated with stem cell transplants from donors carrying a genetic mutation that prevents expression of an HIV receptor CCR5. The subject of the new study has been in remission for 18 months after his antiretroviral therapy (ARV) was discontinued. The authors say it is too early to say with certainty that he has been cured of HIV, and will continue to monitor his condition. “At the moment the only way to treat HIV is with medications that suppress the virus, which people need to take for their entire lives, posing a particular challenge in developing countries,” said the study’s lead author, Pro...